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Sir,
Shigellosis is a global human health problem, espe-
cially in developing countries where there are in-
adequate hygiene and unsafe water supplies (1,2). 
Shigella accounts for a significant proportion of cas-
es of bacillary dysentery in many tropical and sub-
tropical countries (3,4). Shigella is one of the most 
important causes of gastroenteritis-induced deaths 
in 3-5 million children aged less than five years in 
developing countries (5). The emergence of multi-
ple drug resistance to cost-effective antimicrobials 
against Shigella is a matter of concern in developing 
countries (6). It is also well-documented that pan-
demic strains often exhibit multiple antimicrobial 
resistance and induce severe illness with high case 
fatality in all age-groups (7). In the tropics, most in-
fections occur due to S. flexneri and infections that 
occur primarily due to Shigella sonnei are less com-
mon (8,9).
Over a decade ago, results of active surveillance 
studies showed that, in most endemic countries, es-
pecially in Asia and sub-Saharan Africa, there was 
an emergence of multidrug resistance to different 
antimicrobials, including ampicillin, co-trimoxa-
zole, and nalidixic acid (9). 
Besides the temporal changes in the antibiogram 
of Shigella species, it is well-known that antimicro-
bial susceptibility patterns in Shigella may differ 
between geographical areas. Such differences are 
never stable and may change rapidly, especially in 
places where antimicrobials are used excessively, 
particularly in developing countries (1). This war-
rants for robust monitoring of the pattern of anti-
biogram for this organism.
Hence, the present study was conducted to deter-
mine the incidence and prevalence of Shigella se-
rogroups isolated from cases of dysentery during 
a five-year period from 2004 to 2008 and also to 
determine the drug resistance pattern of Shigella in 
a tertiary-care hospital in North India.
In this cross-sectional study, patients presenting 
with acute, bloody diarrhoea, suggestive of shigel-
losis, during 2004-2008, were included. Stool sam-
ples were collected from all patients presenting 
with symptoms of diarrhoea, blood or mucus in 
stool, fever, and abdominal pain. In total, 12,983 
stool samples were received for culture and rou-
tine microscopy during 2004-2008. All the samples 
were subjected to routine microscopy and were ex-
amined for pus cells, trophozoites, and cysts. Only 
those samples which showed pus cells and/or red 
blood cells were cultured. The stool specimens from 
such symptomatic patients were cultured on differ-
ential and selective media, including MacConkey 
agar, Xylose-lysine desoxycholate agar, and deoxy-
cholate citrate agar as primary plates. Loop-full 
sample was also inoculated into selenite-F broth. 
The plates were incubated at 37 oC for 24 hours. 
Suspected colonies on solid plates, which were 
Gram-negative upon Gram-staining and oxidase 
test-negative, were biochemically characterized as 
per standard procedures. Presumptive Shigella iso-
lates on Triple Sugar Iron agar were serotyped by 
slide agglutination tests with Shigella polyvalent 
grouping and monovalent antisera (Denka Seiken 
Co. Ltd., Tokyo, Japan). 
Antimicrobial susceptibility testing and resistance 
patterns of the Shigella isolates to various antimi-
crobials were determined by the disc-diffusion 
technique (10). Every inoculum was prepared by 
inoculating 5 mL of Mueller-Hinton broth with 
five colonies of an 18-hour old pure Shigella culture, 
followed by incubation in ambient air and at 37 ºC 
for 16 hours. Turbidity of the broth was equilibrat-
ed to match with 0.5 McFarland standards. A ster-
ile cotton swab was dipped into the standardized 
suspension, drained, and used for inoculating 25 
mL of Mueller-Hinton agar in a 90-mm plate. The 
inoculating plates were air-dried, and antimicrobial 
discs, included ampicillin (10 μg), chlorampheni-
col (30 μg), co-trimoxazole (25 μg), tetracycline 
(30 μg), gentamicin (10 μg), nalidixic acid (30 μg), Urvashi et al. Antimicrobial resistance pattern of Shigella at tertiary-care centre in India
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No.       % No.       % No.     % No.       %
Ampicillin    94             88.6  70       95.8  20       33.3 3        50  1       100
Co-trimoxazole    90             84.9  69       94.5  18       69.2   2       33.3  1       100
Tetracycline    84             79.2  58       79.4  21       80.7  4      66.6  1       100
Chloramphenicol  58              54  46       63.3  12       46.1 0        00 0        00
Gentamicin   19            17.9  13       17.8 6         23 0        00 0        00
Nalidixic acid  100            94.3  69       94.5 26       100  4      66.6  1       100
Ciprofloxacin  72            67.9  44       60.2  15       57.6 0       00 0        00
Furazolidone  4              3.77  4         5.4 0         00 0       00 0        00
Cefotaxime  19             17.9  12       16.4 6         23 1       16 0        00
Ceftriaxone 13             12.2  10       13.6  3       11.5 0       00 0        00
and ciprofloxacin (5 μg). Furazolidone [Oxoid (UK) 
and Hi-Media (Mumbai, India)] were placed on 
them. The plates were inverted and incubated in 
ambient air at 37 ºC for 18 hours. Zone-sizes were 
measured and compared with those of Escherichia 
coli ATCC25922 which served as a control strain.
Minimum inhibitory concentrations were deter-
mined against ceftriaxone and cefotaxime using 
broth dilution techniques as per the guidelines of 
the Clinical Laboratory Standards Institute (10,11). 
MIC50 and MIC90 were calculated using cumulative 
frequency table.  
In total, 12,983 stool samples were received for 
culture and routine microscopy during 2004-2008. 
Of these samples, 2,109 (16.2%) were from indoor 
patients while the remaining samples were from 
outdoor patients. Upon performing routine mi-
croscopy, only those samples which showed pus 
cells and/or red blood cells were cultured.  In total, 
4,900 such samples were cultured. Shigella species 
were isolated from 106 such patients—74 (69.8%) 
males and 32 (30.1%) females—during 2004-2008. 
The age distribution of patients who were positive 
for Shigella ranged from 23 days to 72 years, with 
a mean age of 17.66 years. The most commonly-
affected age-group was 1-5 years (39.6%), followed 
by the age-group of less than one year (27.3%). All 
the four serogroups were isolated with the follow-
ing distribution: 73 strains of S. flexneri (68.8%), 26 
strains of S. dysenteriae (24.5%), six strains of S. boy-
dii (5.66%), and one strain of S. sonnei (0.9%). Re-
sistance patterns against the applied antimicrobials 
were as follows: nalidixic acid–94.3%; ampicillin–
88.6%; trimethoprim-sulphamethoxazole–84.9%, 
tetracycline–79.2%; ciprofloxacin–67.9%; chloram-
phenicol–54%; and gentamicin–17.9% (Table 1).
Twelve distinct resistance patterns were encoun-
tered in all the Shigella strains tested (Table 2). One 
hundred four isolates (98.11%) were multiple drug-
resistant (MDR). Twelve strains were resistant to 
seven of the eight antimicrobials tested. Sixty-nine 
strains were resistant to six of the eight antimicro-
bials.
MIC90 was calculated at 32 µg/mL while MIC50 was 
found to be 16 µg/mL for both cefotaxime and 
ceftriaxone. Shigellosis occurs both in epidemic 
and endemic forms in children and is a major pub-
lic-health problem in developing countries. This 
retrospective study demonstrated a high level of 
antimicrobial resistance pattern in Shigella species 
isolated from stool samples over a five-year period 
at a tertiary-care teaching hospital in Delhi, north 
India. 
The majority (67%) of the Shigella species were iso-
lated from children aged less than five years, which 
is similar to findings of other studies (4,8). The fact 
that the majority of Shigella isolates are from the 
paediatric population is reported in the literature 
where 70% of all infections occur in children aged 
less than 15 years (1).
The frequency of different species of Shigella varies 
in different countries. The most abundant species 
of Shigella in the present study was S. flexneri which 
is similar to studies in Zahedan, Iran (2,3), Ghana 
(4), and western Nepal (5). A multicentre study by 
Seilden et al. also found S. flexneri as the common-
est species in all, except Thailand where S. sonnei 
was the common isolate (12). A significant longitu-
dinal transition of species from S. flexneri to S. son-
nei and change in antimicrobial resistance pattern 
have been observed in Viet Nam by Vinh et al. (13). Urvashi et al. Antimicrobial resistance pattern of Shigella at tertiary-care centre in India
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R to 10 antimicrobials
  A,T,C,Co,Cf,G,Na,Fx,Ce,Ci 3
R to 9 antimicrobials
  A,T,C,Co,Cf,G,Na,Ce,Ci 1
R to 8 antimicrobials 
  A,T,C,Co,Cf,G,Na,Fx, 1
  A,T,C,Co,Cf,G,Na,Ci 3
  A,T,C,Co,Cf,G,Na,Ce 2
R to 7 antimicrobials
  A,T,C,Co,Cf,Na,Fx 2
  A,T,C,Co,Cf,Na,G 5
  A,T,C,CO,Ce,Ci,G 8
  A,T,Co,Cf,Ci,Na,Fx 4
R to 6 antimicrobials
  A,C,C0,T,Cf,Na 50
  A,C,Co,T,Cf,Ce 2
  A,C,CO,T,Cf,Ci 2
  A,C,Co,Cf,G,T 7
R to 5 antimicrobials
  T,C,Co,Cf,Na 6
  A,T,C,Co,Cf 4
  A,T,C,Cf,Na 1
R to 4 antimicrobials
  A,C,Cf,T 1
R to 3 antimicrobials
  C,Co,Cf 1
  A,C,Co 1
Total 104
A=Ampicillin; C=Chloramphenicol; Ce=Cef-
triaxone; Cf=Ciprofloxacin; Ci=Cefotaxime; 
Co=Co-trimoxazole; Fu=Furazolidone; G=Gent-
amicin; Na=Nalidixic acid; T=Tetracycline
floxacin have been described in Asia (13,15). Also, 
strains of Shigella spp. producing extended-spec-
trum β-lactamases (ESBL) conferring resistance to 
third-generation cephalosporins have also been 
reported (16).                
S. flexneri, the commonest isolate in our study, 
showed a high degree of resistance to most com-
monly-used drugs, such as nalidixic acid (94.3%), 
ampicillin (95.8%), co-trimoxazole (94.5%), tetra-
cycline (79.4%), ciprofloxacin (60.2%), and chlo-
ramphenicol (63.3%). 
In this study, multiple drug resistance to as many 
as seven antimicrobials was observed. Similar find-
ings were reported in other studies from other geo-
graphic areas, such as from Ethiopia and recently 
from Viet Nam (1,13).
Most S. flexneri isolates in our study were suscepti-
ble to gentamicin and furazolidone which support 
the findings of the study conducted by Taneja et al. 
(17). However, the relative increase in the resistance 
to ciprofloxacin (67.2%) in the study by Neogi in 
all Shigella spp., compared to other studies (2,3,5-
7,16), indicates that there is a great need to reduce 
the indiscriminate use of potent antimicrobials, 
such as ciprofloxacin (15). 
Some degree of regulation of antimicrobial use is 
necessary as most antimicrobials are available over-
the-counter and can be bought without any pre-
scription. There is a need to educate both general 
public and health practitioners that most cases of 
diarrhoea do not require antimicrobials. Periodic 
monitoring of drug resistance in enteropathogens 
should be carried out in different geographic areas 
so that an appropriate agent can be chosen for em-
piric therapy. Currently, there are effective optional 
therapies, and ceftriaxone is used as an alternative 
when the patient does not respond to treatment 
with fluoroquinolone. A marked increase in resist-
ance to nalidixic acid and newer fluoroquinolones, 
combined with ESBL-mediated third-generation 
cephalosporin resistance, would leave limited treat-
ment options for those with life-threatening bacte-
rial infections.
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